Home›The Library›Melanotan I
Melanotan I (Afamelanotide)
Afamelanotide and "Melanotan I" are the same molecule — a real, FDA-approved drug (Scenesse, 2019) for a specific, severe photosensitivity disease, with genuine placebo-controlled trial evidence behind it. It is not approved, and was never tested, as a cosmetic tanning agent — the unregulated injectable powder sold online under that name is the same chemical, unapproved for that use and unregulated for purity.
On this page
In brief
Should you care? Yes if you've seen "Melanotan" sold as a tanning injectable — this exact molecule is also a real, approved rare-disease drug, and it's a distinct compound from Melanotan II, this site's separately-covered and more dangerous cousin.The short version
- FDA-approved as Scenesse (2019) for pain-free light exposure in erythropoietic protoporphyria (EPP) — a severe, rare photosensitivity disease.
- Real placebo-controlled trial evidence backs the approval.
- Not approved, and never tested, as a cosmetic tanning agent — the grey-market injectable is unregulated for purity and dosing.
What it is, and its real approval
On 8 October 2019, FDA approved afamelanotide (Scenesse, Clinuvel) — a subcutaneous implant delivering 16mg every two months — to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP), a rare genetic disease causing severe, involuntary pain on sun exposure. It received Priority Review and Orphan Drug designation. This is the same compound originally called Melanotan, or Melanotan-1/Melanotan I, when first developed as a research tool by Victor Hruby and Mac Hadley's lab at the University of Arizona in the early 1980s.
The trial evidence behind the approval
The clinical trial supporting approval found EPP patients on afamelanotide spent a reported median 64 hours over 180 days in direct sunlight between 10am-6pm on pain-free days, versus 41 hours on placebo — a real, measured, clinically meaningful difference for a disease with essentially no other treatment option.
What it isn't approved for
Scenesse is not approved, and was never trialed, as a cosmetic tanning agent for people without EPP. The molecule works by binding the MC1 melanocortin receptor to stimulate melanin production — the same mechanism that makes it darken skin in anyone, which is exactly why it escaped its original disease context and became a grey-market tanning product, sold online as powder for self-injection under the name "Melanotan I" or "Melanotan-1," entirely outside any regulatory oversight of purity or dosing.
An approved implant is not the same as a grey-market vial
Scenesse's approval covers a specific 16mg implant administered by a trained healthcare professional. The self-injected powder sold online for tanning has none of that oversight, regardless of how the marketing borrows the drug's approved credibility.
How it differs from Melanotan II
Melanotan I (afamelanotide) is a linear peptide and a more selective MC1-receptor agonist. Melanotan II is a cyclic peptide that also strongly activates MC3/MC4 receptors — which is why MT-II is associated with the libido effects, and the melanoma and rhabdomyolysis case reports, covered on this site's separate Melanotan II page. Buyers frequently conflate the two; they are related but distinct compounds with materially different risk profiles, and neither grey-market version carries the quality control of the approved implant.
References
- FDA approval, Scenesse (afamelanotide), 8 October 2019 (NDA 210797); Priority Review and Orphan Drug designation (accessdata.fda.gov).
- Pivotal EPP light-exposure trial data (median 64 vs. 41 hours of pain-free sun exposure over 180 days), per FDA review coverage.
- Original [Nle⁴,D-Phe⁷]-α-MSH synthesis (Hadley/Hruby group, University of Arizona) and subsequent naming history as Melanotan/Melanotan-1/afamelanotide.